Skip to main content
Premium Trial:

Request an Annual Quote

INCAPS, Four Pharmas Form Neuroproteomics Consortium; Cancer Project to Follow

NEW YORK, April 5 (GenomeWeb News) - INCAPS - the Indiana Centers for Applied Protein Sciences - and four unnamed pharmaceutical companies have formed a consortium to explore the effect of disease and drug reaction in the central nervous system, INCAPS said today.

 

The fee-for-service research organization said that the focus of the project, called the Neuroproteomics Consortium, is to study neurodegenerative diseases, such as Alzheimer's disease, but that future consortiums on disease areas such as cancer are being planned.

 

Laurie Caviston, INCAPS' vice president of business development, sales and marketing, said that the consortium is a self-funded group, and that the projects will take advantage of commercially available mass spectrometry technology.

 

Caviston declined to provide GenomeWeb News with the identities of the pharmaceutical companies involved, but said that the consortium could make a formal announcement later this month.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.